Cardiorenalmetabolic

Iptacopan Outshines Past C3G Treatments: Carla Nester, MD, MSA, FASN

Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP

Weight Regain After GLP-1 Discontinuation is Less Rapid in Real World: Hamlet Gasoyan, PhD

Cost and Infrastructure Slow Cardiac PET Adoption: Merrill Stewart, MD

Cost and Coverage Issues Drive GLP-1 Discontinuation: Hamlet Gasoyan, PhD

Not All Coronary Blockages Need Fixing: Merrill Stewart, MD

How Can PET Cardiac Stress Testing Prevent Invasive Procedures? Merrill Stewart, MD

Technological Advances in CV Care Depend on Human Resources: Antoine Keller, MD

New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

Lp(a) Awareness Imperative for Enhancing Testing, Prevention Efforts in CVD: Joseph Saseen, PharmD

Personalized Care Key as Tirzepatide Use Expands Rapidly

Engage, Educate, Empower: Transforming Kidney Care